Treatment outcome of patients with anaplastic thyroid cancer: A single center experience

Sun Min Lim, Sang Joon Shin, Woong Youn Chung, Cheong Soo Park, Kee Hyun Nam, Sang Wook Kang, Ki Chang Keum, Joo Hang Kim, Jae Yong Cho, Yun Kyoung Hong, Byoung Chul Cho

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multi-modal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. Materials and Methods: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. Results: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient's condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 months). Conclusion: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.

Original languageEnglish
Pages (from-to)352-357
Number of pages6
JournalYonsei medical journal
Volume53
Issue number2
DOIs
Publication statusPublished - 2012 Mar 1

Fingerprint

Chemoradiotherapy
Survival
Disease-Free Survival
Anaplastic Thyroid Carcinoma
Therapeutics
Kaplan-Meier Estimate
Doxorubicin
Medical Records
Disease Progression
Radiotherapy
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lim, Sun Min ; Shin, Sang Joon ; Chung, Woong Youn ; Park, Cheong Soo ; Nam, Kee Hyun ; Kang, Sang Wook ; Keum, Ki Chang ; Kim, Joo Hang ; Cho, Jae Yong ; Hong, Yun Kyoung ; Cho, Byoung Chul. / Treatment outcome of patients with anaplastic thyroid cancer : A single center experience. In: Yonsei medical journal. 2012 ; Vol. 53, No. 2. pp. 352-357.
@article{30654d25a3c0476588e53a13a84f30b4,
title = "Treatment outcome of patients with anaplastic thyroid cancer: A single center experience",
abstract = "Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multi-modal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. Materials and Methods: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. Results: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient's condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95{\%} CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95{\%} CI, 3.0-4.6 months). Conclusion: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.",
author = "Lim, {Sun Min} and Shin, {Sang Joon} and Chung, {Woong Youn} and Park, {Cheong Soo} and Nam, {Kee Hyun} and Kang, {Sang Wook} and Keum, {Ki Chang} and Kim, {Joo Hang} and Cho, {Jae Yong} and Hong, {Yun Kyoung} and Cho, {Byoung Chul}",
year = "2012",
month = "3",
day = "1",
doi = "10.3349/ymj.2012.53.2.352",
language = "English",
volume = "53",
pages = "352--357",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "2",

}

Lim, SM, Shin, SJ, Chung, WY, Park, CS, Nam, KH, Kang, SW, Keum, KC, Kim, JH, Cho, JY, Hong, YK & Cho, BC 2012, 'Treatment outcome of patients with anaplastic thyroid cancer: A single center experience', Yonsei medical journal, vol. 53, no. 2, pp. 352-357. https://doi.org/10.3349/ymj.2012.53.2.352

Treatment outcome of patients with anaplastic thyroid cancer : A single center experience. / Lim, Sun Min; Shin, Sang Joon; Chung, Woong Youn; Park, Cheong Soo; Nam, Kee Hyun; Kang, Sang Wook; Keum, Ki Chang; Kim, Joo Hang; Cho, Jae Yong; Hong, Yun Kyoung; Cho, Byoung Chul.

In: Yonsei medical journal, Vol. 53, No. 2, 01.03.2012, p. 352-357.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment outcome of patients with anaplastic thyroid cancer

T2 - A single center experience

AU - Lim, Sun Min

AU - Shin, Sang Joon

AU - Chung, Woong Youn

AU - Park, Cheong Soo

AU - Nam, Kee Hyun

AU - Kang, Sang Wook

AU - Keum, Ki Chang

AU - Kim, Joo Hang

AU - Cho, Jae Yong

AU - Hong, Yun Kyoung

AU - Cho, Byoung Chul

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multi-modal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. Materials and Methods: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. Results: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient's condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 months). Conclusion: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.

AB - Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multi-modal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. Materials and Methods: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. Results: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient's condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 months). Conclusion: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.

UR - http://www.scopus.com/inward/record.url?scp=84863171879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863171879&partnerID=8YFLogxK

U2 - 10.3349/ymj.2012.53.2.352

DO - 10.3349/ymj.2012.53.2.352

M3 - Review article

C2 - 22318823

AN - SCOPUS:84863171879

VL - 53

SP - 352

EP - 357

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 2

ER -